There are 2 papers on Myeloma Risk Profile in aging research: 1 observational study in people, 1 review.
2 papers study it3 findings
See all 2 papers on Myeloma Risk Profile
“There was a trend for a shorter median OS in the frail subgroup but without a statistical significance: (frail vs. intermediate or fit): (46 months vs. not reached, HR: 1.94, 95% CI 0.89-4.2, p = 0.094).”
- Humans1
Effects
1Multiple myeloma
no changein humans1HR 0.99
1 study
Multiple myeloma
no changein humans1HR 0.99
Myeloma Risk Profile was not clearly linked with multiple myeloma in humans (elderly newly diagnosed myeloma treated with VCD) (11.8 vs. 9.9 months, HR: 0.99, 95% CI: 0.61-1.61, P = 0.982).
“There was no difference in median PFS between subgroups: (frail vs. intermediate or fit): (11.8 vs. 9.9 months, HR: 0.99, 95% CI: 0.61-1.61, P = 0.982).”
Humanselderly newly diagnosed myeloma treated with VCDn = 100
PloS one
Associations
2Adverse events
upin humans1
1 study
Adverse events
upin humans1
Myeloma Risk Profile is associated with adverse events in humans (elderly newly diagnosed myeloma treated with VCD) (85.5% vs. 71.1%).
“This cohort demonstrated a higher incidence rate of AEs in frail patients compared to those in the intermediate or fit group: patients with at least one any grade toxicity (85.5% vs. 71.1%)”
Humanselderly newly diagnosed myeloma treated with VCDn = 100
PloS one
Mortality
no changein humans1HR 1.94
1 study
Mortality
no changein humans1HR 1.94
Myeloma Risk Profile is associated with mortality in humans (elderly newly diagnosed myeloma treated with VCD) (46 months vs. not reached, HR: 1.94, 95% CI 0.89-4.2, p = 0.094).
“There was a trend for a shorter median OS in the frail subgroup but without a statistical significance: (frail vs. intermediate or fit): (46 months vs. not reached, HR: 1.94, 95% CI 0.89-4.2, p = 0.094).”
Humanselderly newly diagnosed myeloma treated with VCDn = 100
PloS one